All In Biotech

NDA 021894 · Bausch

Xenazine

Tetrabenazine · Oral · Vesicular Monoamine Transporter 2 Inhibitor

NovelPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Sep 13, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2008

Aug 15, 2008

Approved uses

1

Original approval plus efficacy supplements

Registered trials

13

6 Phase 3, 0 recruiting

FAERS reports

7,327

4,082 serious, 1,533 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: DEPRESSION AND SUICIDALITY XENAZINE can increase the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington’s disease. Anyone considering the use of XENAZINE must balance the risks of depression and suicidality with the clinical need for control of chorea. Close observation of patients for the emergence or worsening of depression, suicidality, or unusual changes in behavior should accompany therapy. Patients, their caregivers, and families should be informed of the risk of depression and suicidality and should be instructed to report behaviors of concern promptly to the treating physician. Particular caution should be exercised in treating patients with a history of depression or prior suicide attempts or ideation, which are increased in frequency in Huntington’s disease. XENAZINE is contraindicated in patients who are actively suicidal,...

What it is approved for

From the label in effect Nov 6, 2026.

XENAZINE is indicated for the treatment of chorea associated with Huntington’s disease. XENAZINE is a vesicular monoamine transporter 2 (VMAT) inhibitor indicated for the treatment of chorea associated with Huntington’s disease. ( 1 )

Mechanism: The precise mechanism by which XENAZINE (tetrabenazine) exerts its anti-chorea effects is unknown but is believed to be related to its effect as a reversible depletor of monoamines (such as dopamine, serotonin, norepinephrine, and histamine) from nerve terminals. Tetrabenazine reversibly inhibits the human vesicular monoamine transporter type 2 (VMAT2) (K i ≈ 100 nM), resulting in decreased uptake of monoamines into synaptic vesicles and depletion of monoamine stores. Human VMAT2 is also inhibited by dihydrotetrabenazine (HTBZ), a mixture of α-HTBZ and β-HTBZ. α- and β-HTBZ, major circulating...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • XENAZINE · TETRABENAZINE 12.5MG · TABLET, ORAL · Prescription · TE AB
  • XENAZINE · TETRABENAZINE 25MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Tetrabenazine" as an intervention, any sponsor and status, largest first.

All 13 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death1,222
  • off label use1,138
  • drug ineffective708
  • depression476
  • somnolence451
  • fatigue361
  • fall318
  • hospitalisation301
  • insomnia276
  • intentional product use issue274
  • anxiety263
  • drug administration error241

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20048
20054
20063
20076
20084
2009187
2010450
2011279
2012319
2013353
20141,453
20151,833
2016560
2017699
2018201
2019139
2020145
2021162
2022124
202397
2024119
202591
202691

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Xenazine (Tetrabenazine)

2024 spending

$5.6M

Beneficiaries

23

151 claims

Per beneficiary

$245,537

$291.08 per unit

View as table
YearSpending
2020$22,369,146
2021$14,981,265
2022$10,860,126
2023$9,064,543
2024$5,647,362

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 57 on PubMed

Sponsor: Bausch

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.